Research Topics
| Norah TerraultSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantationNorah A Terrault
University of California San Francisco, San Francisco, CA 64153, USA
Liver Transpl 9:S95-S100. 2003..4. It is unclear whether the preemptive antiviral treatment is superior to delaying treatment until recurrent disease is present and controlled trials addressing this issue are needed...- Treatment of recurrent hepatitis B infection in liver transplant recipientsNorah A Terrault
University of California, San Francisco, CA 64143 0538, USA
Liver Transpl 8:S74-81. 2002..6. Antiviral therapy with two or more suitable agents may minimize the chance for viral resistance; therefore, future therapeutic strategies likely will use combination therapy in the long-term management of recurrent HBV disease... - Sexual activity as a risk factor for hepatitis CNorah A Terrault
Gastroenterology Division, Department of Medicine, University of California, San Francisco, CA 94143, USA
Hepatology 36:S99-105. 2002..Current recommendations about sexual practices are different for persons with chronic HCV infection who are in steady monogamous partnerships versus those with multiple partners or who are in short-term sexual relationships... - Motion - the available treatments for hepatitis C are cost effective: arguments for the motionNorah Terrault
Department of Medicine, University of California, San Francisco 94143 0538, USA
Can J Gastroenterol 16:705-9. 2002..CEAs can facilitate this process by determining which treatment strategies are likely to yield the greatest clinical benefits without excessive expenditures... - Hepatitis B immune globulin preparations and use in liver transplantationNorah A Terrault
Department of Medicine, University of California, 513 Parnassus Avenue, Room S 537, San Francisco, CA 94143 0538, USA
Clin Liver Dis 7:537-50. 2003..Thus, there remains a need to develop and test new forms of anti-HBs therapy, so that effective but less expensive forms of immunoprophylaxis can be made available... - Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspectiveNorah Terrault
University of California at San Francisco, San Francisco, CA, USA
Liver Transpl 11:716-32. 2005 
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysisFrancis Y Yao
Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
Hepatology 48:819-27. 2008..CONCLUSION: Successful down-staging of HCC can be achieved in the majority of carefully selected patients and is associated with excellent posttransplantation outcome...
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation eraCarl L Berg
Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
Hepatology 54:1313-21. 2011..Low MELD candidates with HCC may not benefit from LDLT...- De novo malignancies following liver transplantation: a case-control study with long-term follow-upFrancis Y Yao
Department of Medicine, University of California San Francisco, San Francisco, CA 94143-0538, USA
Clin Transplant 20:617-23. 2006..Patients with non-skin cancer after OLT had diminished long-term survival compared with the controls. Our results differ from other reports in the high incidence of gastrointestinal malignancies with attendant poor prognosis... - Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis CNorah A Terrault
Department of Medicine, University of California San Francisco, San Francisco, California 94143 0538, USA
Clin Gastroenterol Hepatol 6:1403-11. 2008..Prior studies suggest the rate of liver fibrosis progression is slower in African Americans (AAs) than Caucasian Americans (CAs) with chronic HCV infection... - Transplant tourism to China: the impact on domestic patient-care decisionsScott W Biggins
Gastroenterology Heath Outcomes Policy and Economics Research Program, University of California San Francisco, San Francisco, CA 94143 0538, USA
Clin Transplant 23:831-8. 2009..001). Conclusions: Transplant professionals expressed concern about organ procurement practices in China which influenced their patient-care decision-making... - Multidisciplinary management of hepatocellular carcinomaJennifer Guy
Department of Medicine, University of California San Francisco, San Francisco, California, USA
Clin Gastroenterol Hepatol 10:354-62. 2012..We present each specialist's viewpoint on controversies and advances in the management of hepatocellular carcinoma... - Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scoresFrancis Y Yao
Department of Medicine University of California, San Francisco, San Francisco, CA, USA
Hepatology 39:230-8. 2004..In conclusion, our results suggest that severity of graft failure based on CTP and MELD scores may be associated with worse outcome after re-OLT and provide a cautionary note for the "sickest first" policy of organ allocation... - A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agentsK Arnold Chan
Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
Arch Intern Med 163:728-34. 2003..CONCLUSIONS: Acute liver failure or injury not clearly attributable to other known causes occurred on the order of 1 per 10,000 person-years among diabetic patients treated with oral hypoglycemic drugs or insulin... - Hepatitis C virus and lichen planus: a reviewNita Chainani-Wu
Department of Stomatology, Division of Oral Medicine, Oral Pathology, and Oral Radiology, University of California, San Francisco, CA 94143 0658, USA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:171-83. 2004..It is important to determine whether there is an association between OLP and HCV infection so that guidelines regarding the routine HCV testing of patients with OLP can be developed for clinicians... - Treating hepatitis C infection in liver transplant recipientsNorah A Terrault
Department of Medicine Gastroenterology, University of California San Francisco, San Francisco, CA, USA
Liver Transpl 12:1192-204. 2006..Liver Transpl 12:1192-1204, 2006. (c) 2006 AASLD... - Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1Hari S Conjeevaram
Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
Gastroenterology 131:470-7. 2006..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy... - Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activityEithan Galun
Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel
J Hepatol 46:37-44. 2007..A Phase 1 clinical trial was designed to test safety, tolerability, and antiviral activity of HCV-AB68 in patients with chronic HCV-infection... - Evidence-based incorporation of serum sodium concentration into MELDScott W Biggins
University of California San Francisco, San Francisco, California, USA
Gastroenterology 130:1652-60. 2006..CONCLUSIONS: We demonstrate an evidence-based method to incorporate Na into MELD, which provides more accurate survival prediction than MELD alone... - The changing epidemiology and natural history of hepatitis C virus infectionStephanie R Bialek
Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
Clin Liver Dis 10:697-715. 2006..Emerging risk factors for disease progression include steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics... - Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantationNorah A Terrault
Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
Liver Transpl 13:122-9. 2007..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation... - The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatmentNorah A Terrault
Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California, USA
Clin J Am Soc Nephrol 2:563-75. 2007..New antiviral agents that can be used in dialysis patients (e.g., ribavirin alternatives) and in the posttransplantation setting (e.g., IFN alternatives) are needed to improve outcomes in these populations... - Management of hepatitis B in liver transplant recipientsCarla S Coffin
Department of Medicine, University of California at San Francisco, San Francisco, CA 94143, USA
J Viral Hepat 14:37-44. 2007..There is an increasing need for individualization of therapy based on prior drug exposures, level of HBV DNA at time of transplantation and type of prophylaxis used... - Influence of cannabis use on severity of hepatitis C diseaseJulie H Ishida
Department of Medicine, University of California at San Francisco, San Francisco, California, USA
Clin Gastroenterol Hepatol 6:69-75. 2008..Complications of HCV infection are primarily related to the development of advanced fibrosis and whether cannabis use is a risk factor for more severe fibrosis is controversial... - Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infectionFlorian Bihl
Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland
Liver Transpl 14:478-85. 2008..Thus, the profile of the cellular immunity against HBV was in immune suppressed patients similar to subjects with chronic HBV infection with suppressed HBV-DNA... - Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infectionCharles D Howell
University of Maryland Baltimore School of Medicine, Baltimore, Maryland 21201, USA
Clin Gastroenterol Hepatol 6:575-83. 2008.... - Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?Alexander Kuo
J Hepatol 46:359-61. 2007 - Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantationNorah A Terrault
Department of Medicine, University of California at San Francisco, San Francisco, CA 64143 0538, USA
Liver Transpl 12:801-7. 2006..In HIV-HBV coinfected patients undergoing LT, HBV recurrence is successfully prevented with combination prophylaxis using HBIG and antivirals... - Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent yearsMandana Khalili
Department of Medicine, University of California, San Francisco, CA 94110, USA
Clin Transplant 20:1-9. 2006..We conclude that there is considerable variability in the management of HCV among transplant programs and over time... - Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantationSandy Feng
Department of Surgery, Division of Transplantation, University of California, San Francisco, San Francisco, CA 94143-0780, USA
Transplantation 74:1657-63. 2002 - Should HCV-related cirrhosis be a contraindication for retransplantation?Scott W Biggins
Liver Transpl 9:236-8. 2003 - Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy studyPeter G Stock
Department of Surgery, Division of Transplantation, University of California, San Francisco, California 94143 0780, USA
Transplantation 76:370-5. 2003.... - Kidney and liver transplantation in HIV-infected patients: case presentations and reviewMichelle E Roland
Department of Medicine, University of California, San Francisco, San Francisco, California, USA
AIDS Patient Care STDS 17:501-7. 2003.... - Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA)Tarek Elbeik
Department of Laboratory Medicine, University of California, San Francisco 94110, USA
J Clin Microbiol 42:563-9. 2004..1%), a fold change of 2.6. Thus, the observed fold change between any two consecutive HCV RNA measures is expected to be less than 2.6-fold (equivalent to 0.41 log(10) IU/ml) 95% of the time in clinically stable individuals... - New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infectionMandana Khalili
Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA
Liver Transpl 10:349-55. 2004..However, among those developing de novo persistent diabetes, HCV is one of the most important risk factors. This adds further support to the epidemiological data linking HCV and diabetes... - Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfectionAudrey L French
CORE Center Cook County Hospital, Rush Medical College, Chicago, IL 60612, USA
Clin Infect Dis 39:402-10. 2004..65% to increases of 7.57% of the ULN per year; P values of.19-.71). Our findings lend support to assertions that antiretroviral therapy is safe for women with HCV infection... - Antiviral therapy in patients with chronic hepatitis B and cirrhosisCindy J Lai
Division of General Internal Medicine, University of California San Francisco, S357, 513 Parnassus Avenue, San Francisco, CA 94143-0538, USA
Gastroenterol Clin North Am 33:629-54, x-xi. 2004..The newest oral nucleotide analog, adefovir dipivoxil, has shown excellent efficacy in treatment-naïve and lamivudine-resistant HBV patients and has lower rates of resistance in the short-term... - Alcohol use and hepatitis CMarion G Peters
Department of Gastroenterology, University of California, San Francisco, CA 94143, USA
Hepatology 36:S220-5. 2002..The literature is inadequate to provide definitive recommendations regarding the effect of light to moderate alcohol use in patients with hepatitis C... - Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantationRyan A McTaggart
Department of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, CA 94143-0780, USA
Liver Transpl 10:975-85. 2004..Alternatively, the association of HCV and EAR may result from an increased frequency of allograft biopsy and may be further exacerbated by inability to accurately diagnose EAR in the setting of recurrent HCV... - Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver diseaseRolland C Dickson
Division of Gastroenterology and Hepatology, Mayo Clinic Foundation, Jacksonville, FL 32216, USA
Liver Transpl 12:124-33. 2006..In conclusion, this study provides a rationale for the use of lower HBIg doses in HBV patients with suppressed replication undergoing LT... - Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantationAmandeep K Shergill
Department of Medicine, University of California San Francisco, San Francisco, CA, USA
Am J Transplant 5:118-24. 2005..Future studies should focus on alternative dosing schedules with more aggressive use of adjuvant therapies, including GFs... - Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosisDerek Patel
Division of Gastroenterology, Department of Medicine, University of California, 513 Parnassus Avenue, San Francisco, CA 94143-0538, USA
Clin Gastroenterol Hepatol 3:75-84. 2005..By increasing organ availability for timely definitive treatment, LDLT might achieve the greatest gain in life expectancy at acceptable costs. Prioritizing CLT for HCC might increase the population-wide benefits of CLT... - Serum sodium predicts mortality in patients listed for liver transplantationScott W Biggins
Department of Medicine, University of California-San Francisco, San Francisco, CA 94143, USA
Hepatology 41:32-9. 2005..Addition of serum sodium to MELD increases the ability to predict 3- and 6-month mortality in patients with cirrhosis... - Treatment of recurrent hepatitis C in liver transplant recipientsNorah A Terrault
Division of Gastroenterology, University of California at San Francisco, San Francisco, CA 94143 0538, USA
Clin Gastroenterol Hepatol 3:S125-31. 2005..Overall, the treatment of HCV disease in transplant recipients leaves much to be desired and there is an urgent need of new HCV therapies in this patient population... - Treatment of recurrent hepatitis C after liver transplantationScott W Biggins
Division of Gastroenterology, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave, S357, Box 0538 San Francisco, CA 94143, USA
Clin Liver Dis 9:505-23, ix. 2005..Prophylactic and preemptive therapies, as well as treatment of established recurrent disease, are the strategies reviewed... - Sex and hepatitis CNorah A Terrault
Am J Gastroenterol 100:825-6. 2005 - Burden of liver disease in the United States: summary of a workshopW Ray Kim
Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Hepatology 36:227-42. 2002 - Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapyNorah A Terrault
Division of Gastroenterology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
Semin Liver Dis 27:18-24. 2007.... - Outcomes of donor evaluation in adult-to-adult living donor liver transplantationJames F Trotter
Department of Surgery, University of Colorado, Denver, CO, USA
Hepatology 46:1476-84. 2007..CONCLUSION: Both donor and recipient features appear to affect acceptance for LDLT. These findings may aid the donor evaluation process and allow an objective assessment of the likelihood of donor candidate acceptance...